CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Fermer

Novel DYRK1A inhibitors for the treatment of cognitive deficits related to Down’s Syndrome and Alzheimer’s Disease

Référence

05433-01

Statut des brevets

French priority patent application n° FR 12 62275 filed on December 18, 2012

 WO2014096093

Inventeurs

Robert H. DODD
Jean DELABAR
Kevin CARIOU
Stéphanie GOURDAIN
Nathalie JANEL
Fernando RODRIGUES-LIMA
Julien DAIROU
Clément DEHNEZ

Statut commercial

Exclusive or non-exclusive licenses

Laboratoire

Institut de Chimie des Substances Naturelles (ICSN), UPR2301, CNRS, Gif-sur-Yvette, France

Description

CONTEXT

Down’s Syndrome (DS) is the most common genetic disorder with a frequency of 1 in 700 live births worldwide, and it is associated with an increased risk of Alzheimer’s disease. DYRK1A is considered a pathogenic factor in DS and has been implicated in the abnormal hyperphosphorylation of tau protein in Alzheimer’s disease brain.

TECHNICAL DESCRIPTION

The inventors have designed new azaindole-based DYRK1A inhibitors that demonstrate potent activity against DYRK1A and high affinity for the ATP-binding site. In vitro evaluation and computer-guided molecular design were used to select the appropriate candidates. No cytotoxicity has been detected, and primary data obtained on wild-type and DS model mice are very promising. For example, recent studies show that 2 weeks treatment with the new DYRK1A inhibitor was sufficient to improve the performances of DS mice model (Ts65Dn) in the Morris Water Maze.

This work is financially supported by the programme “Emergence of high potential products or services” of the Agence Nationale pour la Recherche.

PUBLICATIONS

Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity.
Gourdain S, Dairou J, Denhez C, Bui LC, Rodrigues-Lima F, Janel N, Delabar JM, Cariou K, Dodd RH.
J Med Chem. 2013 Dec 12;56(23):9569-85

For further information, please contact us (Ref 05433-01)

Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • This field is for validation purposes and should be left unchanged.
Fermer

Les brevets les plus récents